Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets

BMC Vet Res. 2017 Jun 15;13(1):178. doi: 10.1186/s12917-017-1099-z.

Abstract

Background: Marbofloxacin is a veterinary fluoroquinolone with high activity against Pasteurella multocida. We evaluated it's in vivo activity against P. multocida based on in vivo time-kill data in swine using a tissue-cage model. A series of dosages ranging from 0.15 to 2.5 mg/kg were administered intramuscularly after challenge with P. multocida type B, serotype 2.

Results: The ratio of the 24 h area under the concentration-time curve divided by the minimum inhibitory concentration (AUC24TCF/MIC) was the best PK/PD index correlated with the in vivo antibacterial effectiveness of marbofloxacin (R2 = 0.9279). The AUC24TCF/MIC necessary to achieve a 1-log10 CFU/ml reduction and a 3-log10 CFU/ml (90% of the maximum response) reduction as calculated by an inhibitory sigmoid Emax model were 13.48 h and 57.70 h, respectively.

Conclusions: Marbofloxacin is adequate for the treatment of swine infected with P. multocida. The tissue-cage model played a significant role in achieving these PK/PD results.

Keywords: Marbofloxacin; P. Multocida; PK/PD; Piglets; Tissue-cage model.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Fluoroquinolones / pharmacokinetics
  • Fluoroquinolones / therapeutic use*
  • Male
  • Microbial Sensitivity Tests
  • Pasteurella Infections / drug therapy*
  • Pasteurella multocida*
  • Swine
  • Swine Diseases / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • marbofloxacin